rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide

The investigators have developed a phase I/II clinical trial to evaluate the effect of rhIL‐7‐hyFc on lymphocyte counts in patients with high grade glioma (HGG). A phase I study will test whether rhIL‐7‐hyFc can be safely administered to patients with HGG. Six doses of rhIL‐7‐hyFc will be tested using a mix of Accelerated Phase and standard 3+3 dose‐escalation design. The phase II portion to test effect of rhIL‐7‐hyFc on lymphocyte counts will use placebo‐controlled randomization in HGG patients whose treatment include the standard radiation therapy (RT) and temozolomide (TMZ).